Leading the Way in Life Science Technologies

GEN Exclusives

More »
BioMotiv - Related Content
  • Insight & Intelligence™
  • More »
  • Crossing the Valley of Death
    December 20, 2012

    BioMotiv says investments in drugs and technologies, not companies, will bring treatments to market faster.

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »